Introduction {#s1}
============

Glioma is the most common primary central nervous system malignancy in adults, with an annual incidence of 5.26 per 100,000 people ([@B1]). In the WHO classification, grade IV glioma is glioblastoma (GBM) ([@B2]), which is the highest level ([@B3]) in the WHO classification of brain tumors. It is highly malignant ([@B4]) and patients have poor prognosis. It is a kind of cancer that is difficult to treat. Conventional treatments for glioblastoma include surgery, alkylation chemotherapy, and radiotherapy. Traditional treatments are often ineffective, not only because glioblastoma is highly invasive, but also because the blood-brain barrier prevents drugs from killing tumor cells completely. Within 2 cm of the primary site, 77% of GBM will recur ([@B5]). 72% of the cases will recur in field of radiotherapy ([@B6]). These factors are also associated with poor prognosis in patients with GBM.

SEER database (surveillance epidemiology and end results) (<https://seer.cancer.gov/>) is from the National Cancer Institute (NCI). This database records in detail the demographic information, tumor site and morphology, diagnosis stage, treatment and prognosis of millions of patients with malignant tumors and carcinoma *in situ* in some states since 1973 ([@B7]), which provides good data for clinical studies of tumors. Nomogram includes a variety of cancer-related risk factors and presents their impacts on patients\' survival in a visual way. It can personally predict the survival rate of patients and it is a common tool for prognosis assessment of cancer patients ([@B8]--[@B10]). In this study, we extracted the cases of glioblastoma in SEER database from 2007 to 2015, and constructed a nomogram to predict the survival rate of patients and guide clinical prognosis and treatment decisions.

Patients and Methods {#s2}
====================

We used SEER^\*^Stat (version 8.3.4) to collect 128,554 cases of nervous system tumors diagnosed pathologically. Then Excel 2016 was used to perform data cleaning to eliminate invalid data and select patients with glioblastoma from 2009 to 2015 ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}).

###### 

Cleaning of patient demographic data.

  **Variables**                                      **Before cleaning**   **After cleaning**   
  -------------------------------------------------- --------------------- -------------------- -------
  **Age (years)**                                                                               
  0--49                                              48,070                394                  254
  50--54                                             10,044                271                  174
  55--59                                             11,732                309                  238
  60--64                                             12,440                338                  250
  65--69                                             12,476                314                  206
  70--74                                             11,621                267                  160
  75--79                                             10,027                170                  103
  80--84                                             7,011                 93                   52
  85+                                                5,133                 27                   15
  **Race**                                                                                      
  Black                                              8,399                 98                   82
  White                                              112,750               1,981                1,318
  Other                                              6,872                 104                  52
  Unknown                                            533                                        
  **Sex**                                                                                       
  Female                                             56,923                850                  602
  Male                                               71,631                1,333                850
  **Year of diagnosis**                                                                         
  1975--2006                                         73,624                                     
  2007--2009                                         16,058                744                  479
  2010--2012                                         16,341                712                  471
  2013--2015                                         17,078                727                  502
  2016                                               5,453                                      
  **Type of follow-up expected**                                                                
  Active follow-up                                   126,040                                    
  Autopsy/death certificate only cases               2,423                                      
  SF/Oakland only (originally inactive/now active)   91                                         
  **NHIA (Hispanic, Non-Hisp)**                                                                 
  Non-Spanish-Hispanic-Latino                        114,658               1,927                1,288
  Spanish-Hispanic-Latino                            13,896                256                  164
  **Age at diagnosis**                                                                          
  0--49                                              48,070                394                  254
  50--65                                             36,731                980                  705
  66+                                                43,753                809                  493
  **Type of reporting source**                                                                  
  Hospital inpatient/outpatient or clinic            122,674                                    
  Others                                             5,880                                      
  **Insurance**                                                                                 
  Uninsured                                          1,949                 76                   48
  Medicaid                                           7,913                 239                  176
  Insured                                            41,981                1,868                1,228
  Unknown                                            76,711                                     
  **Marital status at diagnosis**                                                               
  Single (never married)                             33,718                309                  208
  Unmarried or domestic partner,                     68,259                1,500                991
  Married (including common law)                                                                
  Separated; Divorced; Widowed                       22,336                374                  253
  Unknown                                            4,241                                      
  **Status**                                                                                    
  Alive                                              30,554                246                  165
  Dead                                               98,000                1,937                1,287

###### 

Cleaning of patient clinical and diagnostic data.

  **Variables**                                                                      **Before cleaning**   **After cleaning**   
  ---------------------------------------------------------------------------------- --------------------- -------------------- -------
  **Site**                                                                                                                      
  Brain                                                                              126,386                                    
  Cranial nerves other nervous system                                                2,168                                      
  **Behavior**                                                                                                                  
  Malignant                                                                          128,554                                    
  **Site ICD-O-3**                                                                                                              
  C710-C719                                                                          126,482               2,183                1,452
  C700                                                                               2,072                                      
  **Histologic type ICD-O-3**                                                                                                   
  944                                                                                62,703                2,183                1,452
  Others                                                                             65,851                                     
  **The degree of differentiation**                                                                                             
  Well; moderately; poorly differentiated                                            18,078                128                  87
  Undifferentiated; anaplastic                                                       34,705                2,055                1,365
  Unknown                                                                            75,771                                     
  **Laterality**                                                                                                                
  Not a paired site                                                                  72,168                259                  173
  Right - origin of primary                                                          27,278                1,011                649
  Left - origin of primary                                                           26,541                913                  630
  Others                                                                             2,567                                      
  **Derived AJCC stage group,7th ed (2010+)**                                                                                   
  Blank(s), NA                                                                       128554                                     
  **Derived AJCC T,7th ed (2010+)**                                                                                             
  Blank(s), NA                                                                       128554                                     
  **Derived AJCC N,7th ed (2010+)**                                                                                             
  Blank(s), NA                                                                       128554                                     
  **Derived AJCC M,7th ed (2010+)**                                                                                             
  Blank(s), NA                                                                       128554                                     
  **Primary site surgery**                                                                                                      
  0                                                                                  27,775                344                  205
  20                                                                                 15,159                415                  265
  21                                                                                 8,838                 413                  263
  30                                                                                 10,792                461                  335
  40                                                                                 12,349                249                  162
  55                                                                                 15,678                301                  222
  10,                                                                                131                   --                   --
  22,                                                                                96                    --                   --
  90, 99, Blank(s)                                                                   37,736                                     
  **Scope region lymph nodes surgery (2003+)**                                                                                  
  Blank(s), unknown or not applicable                                                128554                                     
  **Other region/distance surgery (2003+)**                                                                                     
  Any combo of sur proc to oth rg, dis lym nd, and/or dis site                       8                                          
  None; Blank(s); unknown                                                            128,546                                    
  **Radiation sequence with surgery**                                                                                           
  No radiation and/or cancer-directed surgery                                        71487                 374                  223
  Radiation (or including surgery)                                                   57067                 1,809                1,229
  **Reason no cancer-directed surgery**                                                                                         
  Not recommended or not performed                                                   28,904                344                  205
  Surgery performed                                                                  86,124                1,839                1,247
  Others; unknown                                                                    13,526                                     
  **Radiation**                                                                                                                 
  Refused or non-beam radiation                                                      3,306                 58                   34
  Beam radiation                                                                     73,791                2,125                1,418
  Unknown                                                                            51,457                                     
  **Chemotherapy**                                                                                                              
  No/Unknown                                                                         79,585                                     
  Yes                                                                                48,69                                      
  **Regional nodes examined (1988+)**                                                                                           
  Unknown; blank(s)                                                                  128,554                                    
  **Regional nodes positive (1988+)**                                                                                           
  Unknown; blank(s)                                                                  128554                                     
  **Size**                                                                                                                      
  \<=30 mm                                                                           12,415                467                  316
  \>30, \<=50 mm                                                                     19,842                964                  643
  \>50mm                                                                             15,804                752                  493
  Unknown, size not stated, not stated in patient record; not applicable; Blank(s)   80,493                                     
  **Extension**                                                                                                                 
  All                                                                                128,554                                    
  **Cause-specific death classification**                                                                                       
  Alive or dead of other cause                                                       36,099                336                  219
  Dead (attributable to this cancer dx)                                              77,697                1847                 1233
  Dead (missing/unknown COD)                                                         1,232                                      
  N/A not first tumor                                                                13526                                      
  **Other cause of death classification**                                                                                       
  Alive or dead due to cancer                                                        106,693               2,093                1,398
  Dead (attributable to causes other than this cancer dx)                            7,103                 90                   54
  Dead (missing/unknown COD)                                                         1,232                                      
  N/A not first tumor                                                                13,526                                     
  **Sequence number**                                                                                                           
  One primary only                                                                   111,771               2,145                1,425
  1st of 2 or more primaries                                                         3,257                 38                   27
  Others; unknown                                                                    13,526                                     
  **Frist malignant primary indicator**                                                                                         
  Yes                                                                                115,778                                    
  No                                                                                 12,776                                     
  **Total_malig**                                                                                                               
  1                                                                                  112,208                                    
  2                                                                                  13,925                                     
  3, 4, 5, 6, 7, unknown                                                             2,421                                      
  **Total_begn**                                                                                                                
  0                                                                                  127,149                                    
  1--7, unknown                                                                      1,405                                      

*COD, cause of death; NA, not applicable; ***Total_malig***, total number of in situ/malignant tumors for patient; ***Total_begn***, Total number of benign/borderline tumors for patient. In ***Site ICD-O-3***, code C710-C719 mean "brain or cranial nerves other nervous system," code C700 means "cranial nerves other nervous system." In ***Histologic Type ICD-O-3***, code 944 means glioblastoma. In ***Primary site surgery***, code 0 means "none/no surgery of primary site/autopsy only"; code 10 means "tumor destruction, NOS (not otherwise specified)"; code 20 means "local excision of tumor, lesion, or mass, excisional biopsy"; code 21 means "subtotal resection of tumor, lesion or mass in brain", code 22 means "resection of tumor in spinal cord or nerve"; code 30 means "radical, total, gross resection of tumor, lesion or mass in brain"; code 40 means "partial resection of lobe of brain, when the surgery cannot be coded as 20-30"; code 55 means "gross total resection of lobe of brain (lobectomy)"; code 90 means "surgery, NOS"; 99 means "unknown if surgery performed; death certificate only"*.

The data set partitioning function \[createDataPartition\] in the "caret" package of R version 3.5.3 was used for random grouping, so the cleaned data of patients were randomly divided into training group and verification group. In the training group, "survival" package was used for univariate and multivariate Cox proportional risk regression model analysis to screen prognostic factors, and "rms" package was used to construct nomogram. In nomogram\'s external validation, we calculated the total points of each patient based on the constructed nomogram in the verification group and Cox regression was performed with the total points as a factor. We calculated the C-index and drew calibration curve by Bootstrap method (resampling number B=100) in the training group and the verification group, respectively, for internal and external validation. The higher the C-index is, the more accurate the prognosis is ([@B11]). In the calibration curve, if the predicted value is equal to the actual observed value, the curve will be infinitely close to the ideal 45° slant ([@B12]). Risk score was constructed, and ROC (receiver operating characteristic) curve was derived to evaluate the predicting value. Both the C- index and area under the ROC curve (AUC) can be used to evaluate the discrimination between the real value and the predicted value of the model ([@B12]). Our study procedure is shown in [Figure 1](#F1){ref-type="fig"}.

![The procedure of building a nomogram for patients with glioblastoma. Firstly, we derived patients with nervous system tumors from the SEER database, then selected patients with glioblastoma, and eliminated the invalid data. Secondly, univariate and multivariate Cox regression analysis were performed to obtain individual variables affecting prognosis. Thirdly, individual variables were used to construct nomogram that predicted the prognosis of patients, then internal and external validation were performed.](fonc-10-01051-g0001){#F1}

Results {#s3}
=======

Demographics and Clinicopathologic Characteristics of Patients
--------------------------------------------------------------

This study included the following characteristics into the analysis: age, race, sex, year of diagnosis, degree of differentiation, laterality, primary site surgery, radiation sequence with surgery, reason no cancer-directed surgery, radiotherapy, chemotherapy, tumor size, cause-specific death classification, other cause of death classification, sequence number, NHIA (Hispanic, Non-Hisp), age at diagnosis, insurance, marital status at diagnosis ([Table 3](#T3){ref-type="table"}).

###### 

Univariate and multivariate analyses of prognostic parameter in glioblastoma using the Cox regression model.

  **Variables**                                             **Univariate cox**   **Multivariate cox**                                              
  --------------------------------------------------------- -------------------- ---------------------- ---------------- -------- ---------------- ----------------
  **Age**                                                                                                                                          
  \<50                                                      --                   --                     --               --       --               --
  50--54                                                    1.70116              1.437--2.014           6.88 × 10^−10^   1.154    0.8227--1.6185   0.40702
  55--59                                                    1.65626              1.405--1.953           1.99 × 10^−9^    1.204    0.8605--1.6858   0.27823
  60--64                                                    1.80213              1.536--2.115           5.34 × 10^−13^   1.362    0.9747--1.9046   0.07032
  65--69                                                    2.06971              1.759--2.435           \<2 × 10^−16^    1.734    1.4534--2.0699   1.02 × 10^−9^
  70--74                                                    2.55537              2.157--3.028           \<2 × 10^−16^    1.961    1.6460--2.3371   4.95 × 10^−14^
  75--79                                                    3.699                3.054--4.480           \<2 × 10^−16^    2.678    2.2011--3.2585   \<2 × 10^−16^
  80--84                                                    5.42584              4.276--6.885           \<2 × 10^−16^    3.666    2.8617--4.6966   \<2 × 10^−16^
  ≥85                                                       6.58357              4.428--9.789           \<2 × 10^−16^    3.509    2.3364--5.2689   1.44 × 10^−9^
  **Race**                                                                                                                                         
  Black                                                     --                   --                     --                                         
  White                                                     0.98572              0.7993--1.216          0.8930                                     
  Others                                                    0.74720              0.5553--1.005          0.0543                                     
  **Sex**                                                                                                                                          
  Female                                                    --                   --                     --                                         
  Male                                                      1.02670              0.9367--1.125          0.573                                      
  **Year of diagnosis**                                                                                                                            
  2007--2009                                                --                   --                     --               --       --               --
  2010--2012                                                0.91054              0.8192--1.8192         0.0823           1.114    0.9850--1.2609   0.08540
  2013--2015                                                0.88406              0.7900--0.9893         0.0317           1.524    1.3264--1.7514   2.79 × 10^−9^
  **The degree of differentiation**                                                                                                                
  Well; moderately; poorly differentiated                   --                   --                     --                                         
  Undifferentiated; anaplastic                              1.14822              0.9486 −1.39           0.156                                      
  **Laterality**                                                                                                                                   
  Not a paired site                                         --                   --                     --               --       --               --
  Right                                                     0.66153              0.5749--0.7612         7.80 × 10^−9^    0.8288   0.7185--0.9560   0.00997
  Left                                                      0.62286              0.5405--0.7178         6.16 × 10^−11^   0.7715   0.6678--0.8914   0.00043
  **Surg prim site (1998+)**                                                                                                                       
  0                                                         --                   --                     --                                         
  20                                                        0.56257              0.4850--0.6526         3.10 × 10^−14^                             
  21                                                        0.60341              0.5191--0.7014         4.64 × 10^−11^                             
  30                                                        0.46608              0.4020--0.5404         \<2 × 10^−16^                              
  40                                                        0.63234              0.5356--0.7465         6.27 × 10^−8^                              
  55                                                        0.51739              0.4407--0.6075         8.56 × 10^−16^                             
  **Radiation sequence with surgery**                                                                                                              
  No radiation and/or cancer--directed surgery                                                                                                     
  Radiation (or including surgery)                          0.51393              0.4583--0.5763         \<2 × 10^−16^                              
  **Reason no cancer--directed surgery**                                                                                                           
  Not recommended/not performed                             --                   --                     --                                         
  Surgery performed                                         0.54541              0.4846--0.6138         \<2 × 10^−16^                              
  **Radiation**                                                                                                                                    
  Refused or non--beam radiation                            --                   --                     --                                         
  Beam radiation                                            0.3623               0.2775--0.4729         8.34 × 10^−14^   0.5939   0.3981--0.8859   0.01066
  **Chemotherapy**                                                                                                                                 
  No/unknown                                                --                   --                     --                                         
  Yes                                                       0.41750              0.3672--0.4747         \<2 × 10^−16^    0.5554   0.4829--0.6388   \<2 × 10^−16^
  **Size (mm)**                                                                                                                                    
  ≤30                                                       --                   --                     --                                         
  \>30, ≤50                                                 1.007                0.8952--1.133          0.905                                      
  \>50                                                      1.014                0.8961--1.147          0.826                                      
  **Cause--specific death classification**                                                                                                         
  Alive or dead of other cause                              --                   --                     --                                         
  Dead (attributable to this cancer dx)                     7.3289               5.914--9.083           \<2 × 10^−16^                              
  **Other cause of death classification**                                                                                                          
  Alive or dead due to cancer                               --                   --                     --                                         
  Dead (attributable to causes other than this cancer dx)   7.3289               5.914--9.083           \<2 × 10^−16^                              
  **Sequence number**                                                                                                                              
  One primary only                                          --                   --                     --                                         
  1st of 2 or more primaries                                0.7093               0.4915--1.024          0.0665                                     
  **NHIA (Hispanic, Non--Hisp)**                                                                                                                   
  Non--Spanish--Hispanic--Latino                            --                   --                     --                                         
  Spanish--Hispanic--Latino                                 0.8742               0.7593--1.006          0.0615                                     
  **Age at diagnosis**                                                                                                                             
  0--49                                                     --                   --                     --                                         
  50--65                                                    1.74                 1.525--1.984           \<2 × 10^−16^                              
  ≥66                                                       2.713                2.370--3.104           \<2 × 10^−16^                              
  **Insurance**                                                                                                                                    
  Uninsured                                                 --                   --                     --                                         
  Medicaid                                                  0.9716               0.7397--1.276          0.836                                      
  Insured                                                   1.0055               0.7902--1.279          0.965                                      
  **Marital status at diagnosis**                                                                                                                  
  Single                                                    --                   --                     --                                         
  Married or partner                                        1.19626              1.045--1.369           0.00916                                    
  Separated, divorced or widowed                            1.44977              1.232--1.706           7.86 × 10^−6^                              

*Meaningless variables in statistical results are not listed in this table*.

Independent Prognostic Factors in the Training Group
----------------------------------------------------

The results of the univariate analysis have been listed in [Table 3](#T3){ref-type="table"}. Multivariate Cox analyses demonstrated that age, year of diagnosis, laterality, radiotherapy, chemotherapy were independent risk factors for overall survival (OS) ([Figure 2A](#F2){ref-type="fig"}).

![Survival curves. Survival curve of **(A)** risk score, **(B)** age, **(C)** year of diagnosis, **(D)** laterality, **(E)** radiation, and **(F)** chemotherapy. These graphs show the impact of each subtype on survival. *P* = 0 means *P* \< 0.001.](fonc-10-01051-g0002){#F2}

Prognostic Nomogram for OS
--------------------------

Nomogram was built by the "rms" package in R version 3.5.3 based on the results of multivariate analysis ([Figure 3](#F3){ref-type="fig"}). The *rcorrp.cens* package in *Hmisc* was used to calculate the C-index for measuring the performance of the nomogram. The C-index for OS prediction was 0.729 (95% CI, 0.715--0.743). Calibration curves of 1-, 3-, or 5-years survival rates show good agreement between nomogram predictions and actual observations ([Figures 4A--C](#F4){ref-type="fig"}). In training group, 1-, 3-, and 5-years survival AUCs were 0.722, 0.700, and 0.722, respectively ([Figures 5A--C](#F5){ref-type="fig"}). [Figures 2B--F](#F2){ref-type="fig"} showed the OS of the patients with GBM, and the survival curve declined sharply in the first 20 months.

![Nomogram predicting patients\' 1 -, 3 -, and 5-years over survival with glioblastoma. The specific subtypes of each variables are projected to the point scale to obtain a value. The higher the value, the worse the prognosis of patients. The total value can be obtained by summing up the values of each variables. The 1-year, 3-years, and 5-years over survival of the patient can be obtained by downward projection of the total value in the total point scale. yr_diag, year of diagnosis; later, laterality; radia, radiation; chemo, chemotherapy.](fonc-10-01051-g0003){#F3}

![The calibration curves in training cohort. The calibration curves of the nomogram predicting **(A)** 1-year, **(B)** 3-years, and **(C)** 5-years OS.](fonc-10-01051-g0004){#F4}

![The ROC curves in training cohort. **(A)** 1-year, **(B)** 3-years, **(C)** 5-years survival ROC curves.](fonc-10-01051-g0005){#F5}

Validation of Predictive Accuracy of the Nomogram for OS
--------------------------------------------------------

In the verification group, the C-index of the nomogram for predicting OS was 0.734 (95% CI, 0.718--0.750), and calibration curves showed good agreement between nomogram-predicted probability and actual observations of 1-, 3-, or 5-years survival ([Figures 6A--C](#F6){ref-type="fig"}). In verification group, 1-, 3-, and 5-years survival AUCs were 0.703, 0.672, and 0.640, respectively ([Figures 7A--C](#F7){ref-type="fig"}).

![The calibration curves in verification cohort. The calibration curves of the nomogram predicting **(A)** 1-year, **(B)** 3-years, and **(C)** 5-years OS.](fonc-10-01051-g0006){#F6}

![The ROC curves in verification cohort. **(A)** 1-year, **(B)** 3-years, **(C)** 5-years survival ROC curves.](fonc-10-01051-g0007){#F7}

Discussion {#s4}
==========

Accurate and effective prognosis assessment is of clinical significance for individualized treatment and follow-up treatment of patients with GBM. GBM is usually diagnosed in late stage ([@B13]) by MRI with poor prognosis, therefore, a complete prognostic scoring system is essential. Nomogram is a statistical tool that integrates a variety of prognostic risk factors and visualizes the overall impact of these risk factors on survival in each patient ([@B14]) to help clinicians develop intervention plan. Compared with other rating systems (such as AJCC 8th edition TNM staging system and the Nathan staging system), nomogram is more convenient and accurate, with a higher C-index, showing better predictive value ([@B15], [@B16]). Many scholars have produced nomograms for some tumors, such as intrahepatic cholangiocarcinoma ([@B17]), invasive pulmonary adenocarcinoma ([@B18]), colorectal cancer ([@B19]), hepatocellular carcinoma with pulmonary metastasis ([@B20]), etc. SEER collects 450,000 cancer cases with high-quality information each year, and adjusts the collection of cancer staging information according to changes in cancer staging systems, such as AJCC ([@B7]). So that it provides a good data basis for establishing of nomogram.

To construct the nomogram, independent predictors of OS in patients with GBM should be determined first. Univariate and multivariate Cox proportional risk regression models were used to determine independent prognostic factors for OS. Multivariate Cox regression proportional analysis showed that age, year of diagnosis, laterality, radiation, chemotherapy were independent prognostic factors for OS in patients with GBM.

It is an acceptable view that the prognosis of cancer patients is worse with aging. Ladomersky et al. analyzed several databases (SEER, GTEx, and 10 k Immunomes) and found that the death rate of patients with GBM over 65 years old was more than seven times higher than that of patients under 65 years old, thus the prognosis of patients with GBM over 65 years old was much worse than that of patients with GBM under 65 years old ([@B21]). In our study, the results of multivariate analysis further showed that, for patients aged at least 65 years old, the older they were, the higher the HR (hazard ratio) was and the worse the prognosis was. That was similar to the results of Bartek\'s SEER based study, which showed a 0.8% increased risk of death from glioblastoma with each additional year of age at diagnosis (CI 1.008--1.008, *p* \< 0.001) ([@B22]). Elderly patients are more likely to develop other high-risk complications ([@B23]--[@B26]). In addition, aging may promote the initiation or growth of GBM cells by suppressing the immune system, and may reduce the effectiveness of immunotherapy for patients with glioblastoma ([@B21]). All those will reduce the prognostic survival rate of patients with GBM.

For newly diagnosed glioblastoma, the most important treatment is the resection of the contrast-enhanced region on imaging, followed by radiotherapy and chemotherapy ([@B27], [@B28]). The results of our multivariate analysis showed that both beam radiotherapy and chemotherapy can immensely reduce the risk of patients with glioblastoma and improve the survival rate. Yaprak et al. ([@B29]) and Liao et al. ([@B30]) proved the feasibility of radiotherapy for glioblastoma. In our study, the prognosis of patients with beam radiation therapy was better than with non-beam radiation therapy (including radioactive implants, brachytherapy, radioisotopes, etc.) or without radiotherapy. In addition, the results of our study indicate that patients with chemotherapy have a significantly higher survival rate than those without chemotherapy. This may be an important role played by temozolomide, the first-line chemotherapy drug for glioblastoma. Temozolomide\'s introduction significantly improved the prognosis of patients with glioblastoma. The Stupp protocol, proposed in 2005, is the standard of treatment for glioblastoma. It includes radiotherapy, concomitant and adjuvant chemotherapy with temozolomide ([@B28]). This kind of treatment significantly improved survival. Perry et al. ([@B31]) randomly divided 562 newly diagnosed glioblastoma patients over the age of 65 into two groups, one receiving only short-term radiation therapy and the other receiving short-term radiation therapy plus adjuvant temozolomide. The results showed that the median overall survival of patients who received radiotherapy with temozolomide was longer than those who received chemotherapy alone (5.3 months vs. 3.9 months; *P* \< 0.001).

The impact of tumor laterality on the prognosis of patients has not been fully investigated so far. Daniel et al. retrospectively analyzed 235 cases of patients with glioblastoma on surgical outcome, which were grouped for left---and right---sided GBM ([@B32]). The results showed that KPS (Karnofsky Performance Status) decreased significantly and PFS (progression-free survival) was shorter in patients with left hemisphere tumors, but their OS was not significantly different from those in patients with right hemisphere tumors. In our study, patients whose tumor originated at paired site (e.g., left or right hemisphere) had a better prognosis than those whose tumor originated at non-paired site. And patients whose tumors originated at the left had a lower risk than those whose tumors that originated at the right. Tumor laterality may be a noteworthy prognostic factor because different regions of the brain perform different functions, and neurologists may use conservative therapy to preserve some of the patient\'s functions for need.

Based on the above results, we propose the following suggestions for the treatment of patients with glioblastoma. Pay attention to the age of the patient, especially those aged 65 or older, because elderly people have a worse prognosis. Radiotherapy (especially beam radiotherapy) and chemotherapy should be used, as they can significantly improve the prognosis of patients with glioblastoma. Increase attention to tumor laterality, it may also be a potential prognostic factor.

However, our study has some limitations. Firstly, the SEER database does not include information about tumor markers, such as MGMT (O (6)-methylguanine-DNA methyltransferase) promoter methylation ([@B33]) and IDH (isocitrate dehydrogenase) mutation ([@B34]), and the two markers have strong prognostic value in patients with glioblastoma. Secondly, the SEER database lacks records of neurological interventions, so this study was not discussed. Thirdly, the study objects of SEER, the American clinical database of tumors, are predominantly white people and black people but few Asians. That partly limited the application of our nomogram in Asian patients. Fourthly, as a retrospective study, both the training group and the verification group may be affected by selection bias.

Conclusion {#s5}
==========

In conclusion, nomogram integrates easily available factors and serves as an easy-to-use tool to assist patients with glioblastoma in risk assessment and clinical decision-making. The nomogram proposed in this study may objectively and accurately predict 1-, 3, and 5-year OS of patients with glioblastoma. Additional studies are needed to determine whether it is appropriate for the other patient group.
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